Cover Image
市場調查報告書

腹瀉:開發中產品分析

Diarrhea - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192560
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
Back to Top
腹瀉:開發中產品分析 Diarrhea - Pipeline Review, H2 2016
出版日期: 2016年07月20日 內容資訊: 英文 164 Pages
簡介

腹瀉主要是由於不衛生條件所導致的接觸性傳染之胃腸感染病。腹瀉也可能與病毒或細菌感染有關,此外食物中毒也常是原因之一。其症狀有噁心、腹痛、肌肉痙攣、腫脹、脫水、發熱、血便、為了排便而處於頻繁的尿意及失禁等。治療法包含投藥療法及健康性的生活方式。

本報告網羅全球腹瀉治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,再加上主要企業及開發中的產品檢討等。

目錄

簡介

  • 分析範圍

腹瀉概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥 - 各企業

開發中的治療藥 - 大學/研究機關

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品 - 各企業

開發中的產品 - 大學/研究機關

治療藥的開發企業

  • Ipsen S.A.
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Shire Plc
  • Mucosis B.V
  • Helsinn Healthcare S.A.
  • Ventria Bioscience.
  • Ache Laboratorios Farmaceuticos S/A
  • Ocera Therapeutics, Inc.
  • GP Pharm, S.A.
  • Tioga Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Aegis Therapeutics, LLC
  • Drais Pharmaceuticals, Inc.
  • DesignMedix, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Rottapharm¦Madaus
  • Sanofi Pasteur SA
  • Inhibikase Therapeutics, Inc.
  • Rebiotix Inc

治療藥的評估

  • 單劑治療藥
  • 標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 產品概要
  • 作用機制
  • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8281IDB

Summary

Global Markets Direct's, 'Diarrhea - Pipeline Review, H2 2016', provides an overview of the Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diarrhea
  • The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects
  • The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diarrhea

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diarrhea
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diarrhea Overview
  • Therapeutics Development
    • Pipeline Products for Diarrhea - Overview
    • Pipeline Products for Diarrhea - Comparative Analysis
  • Diarrhea - Therapeutics under Development by Companies
  • Diarrhea - Therapeutics under Investigation by Universities/Institutes
  • Diarrhea - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Diarrhea - Products under Development by Companies
  • Diarrhea - Products under Investigation by Universities/Institutes
  • Diarrhea - Companies Involved in Therapeutics Development
    • A. Menarini Industrie Farmaceutiche Riunite Srl
    • Ache Laboratorios Farmaceuticos S/A
    • Actelion Ltd
    • Aegis Therapeutics, LLC
    • AlbireoPharma
    • Allergan Plc
    • Anatara Lifesciences Limited
    • Ardelyx, Inc.
    • Assembly Biosciences, Inc.
    • Codagenix, Inc.
    • Cosmo Pharmaceuticals S.p.A
    • DesignMedix, Inc.
    • DiscoveryBiomed, Inc.
    • Genextra S.p.a.
    • GlaxoSmithKline Plc
    • GP Pharm, S.A.
    • Mucosis B.V.
    • Nippon Shinyaku Co., Ltd.
    • Novartis AG
    • Pfizer Inc.
    • Prokarium Limited
    • Protagonist Therapeutics Inc.
    • Rebiotix Inc.
    • Recce Pty Ltd
    • RxBio, Inc.
    • Scandinavian Biopharma Holding AB
    • Sigmoid Pharma Limited
    • Summit Therapeutics Plc
    • Synthetic Biologics, Inc.
    • Syntiron LLC
    • Tasly Pharmaceutical Group Co., Ltd.
  • Diarrhea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABM-101 - Drug Profile
    • ACH-04 - Drug Profile
    • ASP-7147 - Drug Profile
    • cadazolid - Drug Profile
    • Campylobacter jejuni [strain CPS81-176] vaccine - Drug Profile
    • cholestyramine - Drug Profile
    • Clostridium difficile vaccine - Drug Profile
    • crofelemer DR - Drug Profile
    • Drug for Diarrhea - Drug Profile
    • eluxadoline - Drug Profile
    • Escherichia coli vaccine - Drug Profile
    • ETEC vaccine - Drug Profile
    • ETEC vaccine - Drug Profile
    • Etvax - Drug Profile
    • GVXNSD-133 - Drug Profile
    • GXG-8 - Drug Profile
    • ibodutant - Drug Profile
    • IMSUTMR-1501 - Drug Profile
    • infectious diarrhea [serotype H11] vaccine - Drug Profile
    • LJN-452 - Drug Profile
    • obeticholic acid - Drug Profile
    • octreotide acetate - Drug Profile
    • octreotide acetate MAR - Drug Profile
    • Peptide to Activate NHE-3 for Diarrhea - Drug Profile
    • PF-06425090 - Drug Profile
    • prulifloxacin - Drug Profile
    • PZ-7475 - Drug Profile
    • RBX-2660 - Drug Profile
    • RDX-98940 - Drug Profile
    • RECCE-355 - Drug Profile
    • Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile
    • Recombinant Proteins for Infectious Diarrhea - Drug Profile
    • ribaxamase - Drug Profile
    • ridinilazole - Drug Profile
    • rifamycin CR - Drug Profile
    • Rx-100 - Drug Profile
    • Small Molecule to Block CFTR for Diarrhoea - Drug Profile
    • Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile
    • Small Molecules for Microbial Infections - Drug Profile
    • Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea - Drug Profile
    • Small Molecules to Inhibit CFTR for Secretory Diarrhea - Drug Profile
    • SYN-006 - Drug Profile
    • SYN-007 - Drug Profile
    • Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea - Drug Profile
    • Typhetec - Drug Profile
    • Vaccine 1 for Diarrhea - Drug Profile
    • Vaccine 2 for Diarrhea - Drug Profile
    • Vaccine for Traveler's Diarrhea - Drug Profile
    • Vaccine for Traveler's Diarrhea - Drug Profile
    • Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea - Drug Profile
    • Yersinia pestis vaccine - Drug Profile
  • Diarrhea - Dormant Projects
  • Diarrhea - Discontinued Products
  • Diarrhea - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diarrhea, H2 2016
  • Number of Products under Development for Diarrhea - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diarrhea - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016
  • Diarrhea - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016
  • Diarrhea - Pipeline by Actelion Ltd, H2 2016
  • Diarrhea - Pipeline by Aegis Therapeutics, LLC, H2 2016
  • Diarrhea - Pipeline by AlbireoPharma, H2 2016
  • Diarrhea - Pipeline by Allergan Plc, H2 2016
  • Diarrhea - Pipeline by Anatara Lifesciences Limited, H2 2016
  • Diarrhea - Pipeline by Ardelyx, Inc., H2 2016
  • Diarrhea - Pipeline by Assembly Biosciences, Inc., H2 2016
  • Diarrhea - Pipeline by Codagenix, Inc., H2 2016
  • Diarrhea - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016
  • Diarrhea - Pipeline by DesignMedix, Inc., H2 2016
  • Diarrhea - Pipeline by DiscoveryBiomed, Inc., H2 2016
  • Diarrhea - Pipeline by Genextra S.p.a., H2 2016
  • Diarrhea - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Diarrhea - Pipeline by GP Pharm, S.A., H2 2016
  • Diarrhea - Pipeline by Mucosis B.V., H2 2016
  • Diarrhea - Pipeline by Nippon Shinyaku Co., Ltd., H2 2016
  • Diarrhea - Pipeline by Novartis AG, H2 2016
  • Diarrhea - Pipeline by Pfizer Inc., H2 2016
  • Diarrhea - Pipeline by Prokarium Limited, H2 2016
  • Diarrhea - Pipeline by Protagonist Therapeutics Inc., H2 2016
  • Diarrhea - Pipeline by Rebiotix Inc., H2 2016
  • Diarrhea - Pipeline by Recce Pty Ltd, H2 2016
  • Diarrhea - Pipeline by RxBio, Inc., H2 2016
  • Diarrhea - Pipeline by Scandinavian Biopharma Holding AB, H2 2016
  • Diarrhea - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Diarrhea - Pipeline by Summit Therapeutics Plc, H2 2016
  • Diarrhea - Pipeline by Synthetic Biologics, Inc., H2 2016
  • Diarrhea - Pipeline by Syntiron LLC, H2 2016
  • Diarrhea - Pipeline by Tasly Pharmaceutical Group Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diarrhea - Dormant Projects, H2 2016
  • Diarrhea - Dormant Projects (Contd..1), H2 2016
  • Diarrhea - Dormant Projects (Contd..2), H2 2016
  • Diarrhea - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diarrhea, H2 2016
  • Number of Products under Development for Diarrhea - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top